PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 47/48, 49/00, 49/04, 51/10 — A1

(11) International Publication Number: WO 00/02587

(43) International Publication Date: 20 January 2000 (20.01.00)

(21) International Application Number: PCT/US99/15668

(22) International Filing Date: 12 July 1999 (12.07.99)

(30) Priority Data:

60/092,589	13 July 1998 (13.07.98)	US
60/110,600	2 December 1998 (02.12.98)	US

(71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 701 West 7th Street, Austin, TX 78701 (US).

(72) Inventors: THORPE, Philip, E.; 6722 Lakewood, Dallas, TX 75214 (US). RAN, Sophia; 5840 Spring Valley Road #1612, Dallas, TX 75240 (US).

(74) Agent: FUSSEY, Shelley, P., M.; Williams, Morgan & Amerson, Suite 250, 7676 Hillmont, Houston, TX 77040 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: CANCER TREATMENT METHODS USING THERAPEUTIC CONJUGATES THAT BIND TO AMINOPHOSPHOLIPIDS

(57) Abstract

Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid–targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody–therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably–expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.